Scynexis (SCYX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.67, -6.14% vs the prior close of $3.91.
- Volume 188.85K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SCYX slides 6.1% to $3.67, a 1-month low, 11 down days in a row. Closed at $3.67, -6.14% vs the prior close of $3.91. Day range $3.54–$3.88, opened at $3.87.
SCYX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SCYX slides 6.1% to $3.67, a 1-month low, 11 down days in a row
- Closed at $3.67, -6.14% vs the prior close of $3.91. Day range $3.54–$3.88, opened at $3.87.
- Volume was 188.85K shares, 0.7x its 50-day average of 267.63K.
- Price is -23.8% vs its 50-day average ($4.82) and -34.6% vs its 200-day average ($5.61).
- 52-week range $3.53–$9.12; today's close sits at 3% of that range, 59.8% below the 52-week high.
- That makes 11 straight losses.
Oct 15, 2026 — SCYX dips 1.3% to $3.91, a 1-month low, 10 down days in a row
- Closed at $3.91, -1.26% vs the prior close of $3.96. Day range $3.78–$3.97, opened at $3.96.
- Volume was 69.70K shares, 0.3x its 50-day average of 268.16K — lighter than usual.
- Price is -19.4% vs its 50-day average ($4.85) and -30.4% vs its 200-day average ($5.62).
- 52-week range $3.53–$9.12; today's close sits at 7% of that range, 57.1% below the 52-week high.
- That makes 10 straight losses.
Oct 14, 2026 — SCYX dips 0.8% to $3.96, a 1-month low, 9 down days in a row
- Closed at $3.96, -0.75% vs the prior close of $3.99. Day range $3.90–$4.08, opened at $4.00.
- Volume was 44.60K shares, 0.2x its 50-day average of 270.83K — lighter than usual.
- Price is -18.7% vs its 50-day average ($4.87) and -29.6% vs its 200-day average ($5.62).
- 52-week range $3.53–$9.12; today's close sits at 8% of that range, 56.6% below the 52-week high.
- That makes 9 straight losses.
Oct 13, 2026 — SCYX dips 1.0% to $3.99, a 1-month low, 8 down days in a row
- Closed at $3.99, -0.99% vs the prior close of $4.03. Day range $3.92–$4.09, opened at $4.03.
- Volume was 66.70K shares, 0.2x its 50-day average of 278.15K — lighter than usual.
- Price is -18.6% vs its 50-day average ($4.90) and -29.1% vs its 200-day average ($5.63).
- 52-week range $3.53–$9.12; today's close sits at 8% of that range, 56.2% below the 52-week high.
- That makes 8 straight losses.
Oct 12, 2026 — SCYX dips 1.2% to $4.03, a 1-month low, 7 down days in a row
- Closed at $4.03, -1.23% vs the prior close of $4.08. Day range $4.00–$4.15, opened at $4.05.
- Volume was 68.00K shares, 0.2x its 50-day average of 340.48K — lighter than usual.
- Price is -18.2% vs its 50-day average ($4.92) and -28.4% vs its 200-day average ($5.63).
- 52-week range $3.53–$9.12; today's close sits at 9% of that range, 55.8% below the 52-week high.
- That makes 7 straight losses.
Oct 9, 2026 — SCYX slides 3.3% to $4.08, a 1-month low, 6 down days in a row
- Closed at $4.08, -3.32% vs the prior close of $4.22. Day range $4.02–$4.23, opened at $4.19.
- Volume was 119.50K shares, 0.4x its 50-day average of 339.26K — lighter than usual.
- Price is -17.4% vs its 50-day average ($4.94) and -27.6% vs its 200-day average ($5.63).
- 52-week range $3.53–$9.12; today's close sits at 10% of that range, 55.3% below the 52-week high.
- That makes 6 straight losses.
Oct 8, 2026 — SCYX slides 11.7% to $4.22, 5 down days in a row
- Closed at $4.22, -11.72% vs the prior close of $4.78. Day range $4.11–$4.75, opened at $4.70.
- Volume was 344.20K shares, 1.0x its 50-day average of 333.32K.
- Price is -14.5% vs its 50-day average ($4.93) and -25.2% vs its 200-day average ($5.64).
- 52-week range $3.53–$9.12; today's close sits at 12% of that range, 53.7% below the 52-week high.
- That makes 5 straight losses.
Oct 7, 2026 — SCYX dips 1.2% to $4.78, 4 down days in a row
- Closed at $4.78, -1.24% vs the prior close of $4.84. Day range $4.75–$5.04, opened at $4.86.
- Volume was 80.50K shares, 0.2x its 50-day average of 332.25K — lighter than usual.
- Price is -2.9% vs its 50-day average ($4.92) and -15.3% vs its 200-day average ($5.64).
- 52-week range $3.53–$9.12; today's close sits at 22% of that range, 47.6% below the 52-week high.
- That makes 4 straight losses.
Oct 6, 2026 — SCYX slides 3.8% to $4.84, 3 down days in a row
- Closed at $4.84, -3.78% vs the prior close of $5.03. Day range $4.79–$5.29, opened at $5.10.
- Volume was 162.40K shares, 0.5x its 50-day average of 331.08K — lighter than usual.
- Price is -1.2% vs its 50-day average ($4.90) and -14.2% vs its 200-day average ($5.64).
- 52-week range $3.53–$9.12; today's close sits at 23% of that range, 46.9% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — SCYX dips 1.8% to $5.03
- Closed at $5.03, -1.76% vs the prior close of $5.12. Day range $4.83–$5.20, opened at $5.09.
- Volume was 356.00K shares, 1.1x its 50-day average of 325.78K.
- Price is +3.2% vs its 50-day average ($4.88) and -10.9% vs its 200-day average ($5.65).
- 52-week range $3.53–$9.12; today's close sits at 27% of that range, 44.8% below the 52-week high.
Oct 2, 2026 — SCYX slides 4.7% to $5.12
- Closed at $5.12, -4.66% vs the prior close of $5.37. Day range $5.09–$5.51, opened at $5.32.
- Volume was 132.40K shares, 0.4x its 50-day average of 323.77K — lighter than usual.
- Price is +5.6% vs its 50-day average ($4.85) and -9.3% vs its 200-day average ($5.65).
- 52-week range $3.53–$9.12; today's close sits at 28% of that range, 43.9% below the 52-week high.
SCYX latest news & SEC filings
Every SEC filing by or about SCYX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Burke Steven Keith received an award of 5,750 shares on Sep 18, 2026; now holds 5,750
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 11, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $235.00K (prior year $1.36M) (-82.8% vs Jun 30, 2025)
- Net income: $7.40M (prior year -$6.88M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $0.63 (prior year -$1.11) (swung to profit vs Jun 30, 2025)
Jul 20, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade SCYX
- Last results release: Mar 28, 2024 (8-K Item 2.02). Previous ones: Nov 9, 2022, Aug 15, 2022, May 12, 2022. Based on that rhythm, the next report is likely around Jun 27, 2024 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.97% (largest 11.7%). That is a volatile stock.
- Liquidity: about 560.73K shares (≈$2.06M) trade per day on average.
- 52-week position: $3.67 vs a range of $3.53–$9.12 (3% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:8 on Jun 1, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: Gonzalez David Angulo bought 108,695 shares on Apr 1, 2026.
- Latest filings: 8-K Sep 28, 2026; 8-K Sep 22, 2026; 8-K Sep 10, 2026.
- Share count: 9.95M shares outstanding (Aug 1, 2026), -76.3% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SCYX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.87 | 3.88 | 3.54 | 3.67 | 188.85K |
| Oct 15, 2026 | 3.96 | 3.97 | 3.78 | 3.91 | 69.70K |
| Oct 14, 2026 | 4.00 | 4.08 | 3.90 | 3.96 | 44.60K |
| Oct 13, 2026 | 4.03 | 4.09 | 3.92 | 3.99 | 66.70K |
| Oct 12, 2026 | 4.05 | 4.15 | 4.00 | 4.03 | 68.00K |
| Oct 9, 2026 | 4.19 | 4.23 | 4.02 | 4.08 | 119.50K |
| Oct 8, 2026 | 4.70 | 4.75 | 4.11 | 4.22 | 344.20K |
| Oct 7, 2026 | 4.86 | 5.04 | 4.75 | 4.78 | 80.50K |
| Oct 6, 2026 | 5.10 | 5.29 | 4.79 | 4.84 | 162.40K |
| Oct 5, 2026 | 5.09 | 5.20 | 4.83 | 5.03 | 356.00K |
| Oct 2, 2026 | 5.32 | 5.51 | 5.09 | 5.12 | 132.40K |
| Oct 1, 2026 | 4.99 | 5.50 | 4.86 | 5.37 | 600.50K |
| Sep 30, 2026 | 4.65 | 5.03 | 4.56 | 4.94 | 310.20K |
| Sep 29, 2026 | 4.62 | 4.80 | 4.52 | 4.66 | 538.20K |
| Sep 28, 2026 | 4.60 | 5.14 | 4.45 | 4.62 | 7.78M |
| Sep 25, 2026 | 4.58 | 4.58 | 4.37 | 4.39 | 31.60K |
| Sep 24, 2026 | 4.58 | 4.81 | 4.41 | 4.45 | 38.00K |
| Sep 23, 2026 | 4.93 | 5.00 | 4.42 | 4.64 | 65.50K |
| Sep 22, 2026 | 4.47 | 4.94 | 4.36 | 4.86 | 167.70K |
| Sep 21, 2026 | 4.59 | 4.59 | 4.27 | 4.40 | 45.90K |
About Scynexis
Scynexis (SCYX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in JERSEY CITY, NJ. Fiscal year ends December 31. SEC CIK 1178253.
SCYX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Armando Anido | Director | Jun 30, 2026 |
| Gonzalez David Angulo | Chief Executive Officer | Apr 2, 2026 |
| Steven Keith Burke | Director | Sep 22, 2026 |
| Ann Hanham | Director | Jun 30, 2026 |
| David C Hastings | Director | Jun 30, 2026 |
| Guy Macdonald | Director | Jun 30, 2026 |
| Brian Philippe Tinmouth | Director | Jun 30, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Gonzalez David Angulo | Chief Executive Officer | Apr 2, 2026 |
| Ivor Macleod | Chief Financial Officer | Feb 2, 2026 |
| Sanjay Subramanian | Chief Financial Officer | Sep 11, 2026 |
| Scott Sukenick | Chief Legal Officer | Feb 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 1, 2026 | Gonzalez David Angulo | Buy | 108,695 | — |
| Apr 1, 2026 | Gonzalez David Angulo | Buy | 108,695 | — |
| Apr 1, 2026 | Gonzalez David Angulo | Buy | 108,695 | — |
| Apr 1, 2026 | Gonzalez David Angulo | Buy | 108,695 | — |
SCYX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $20.60M | $-8.61M | -0.17 | $-5.28M |
| Dec 31, 2024 | $3.75M | $-21.29M | -0.44 | $-24.01M |
| Dec 31, 2023 | $140.14M | $67.04M | 1.39 | $60.16M |
| Dec 31, 2022 | $5.09M | $-62.81M | -1.47 | $-79.88M |
| Dec 31, 2021 | $13.16M | $-32.87M | -1.25 | $-54.56M |
Latest balance sheet: total assets $74.97M, total liabilities $8.04M, cash $10.49M (as of Jun 30, 2026).
SCYX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Mar 28, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2022 | 8-K Item 2.02 (results) | — |
| Aug 15, 2022 | 8-K Item 2.02 (results) | — |
| May 12, 2022 | 8-K Item 2.02 (results) | — |
| Mar 29, 2022 | 8-K Item 2.02 (results) | — |
| Nov 10, 2021 | 8-K Item 2.02 (results) | — |
| Mar 5, 2018 | 8-K Item 2.02 (results) | — |
| Oct 5, 2016 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SCYX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.